The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2020
Filed:
May. 19, 2017
Applicant:
Hoffmann-la Roche Inc., Little Falls, NJ (US);
Inventors:
Christian Klein, Bonstetten, CH;
Vaios Karanikas, Adliswil, CH;
Pablo Umana, Wollerau, CH;
Alfred Zippelius, Basel, CH;
Daniela Stefanie Thommen, Basel, CH;
Jens Schreiner, Basel, CH;
Assignee:
Hoffmann-La Roche Inc., Little Falls, NJ (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/3023 (2013.01); C07K 16/3046 (2013.01); C07K 16/3069 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/35 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/55 (2013.01);
Abstract
The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.